Statin use and the risk of bladder cancer: a population-based case–control study

Bibliography

• Wong WW, Dimitroulakos J, Minden MD, HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-19
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Hebert PR, Gaziano JM, Chan KS, Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-21
   PubMed Web of Science ®Google Scholar
• Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Sandoval L, Band V, Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602-9
   PubMed Web of Science ®Google Scholar
• Dimitroulakos J, Marhin WH, Tokunaga J, Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinoma. Neoplasia 2002;4:337-46
   PubMed Web of Science ®Google Scholar
• Park HJ, Hong D, Iruela-Arispe L, 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002;91:143-50
   PubMed Web of Science ®Google Scholar
• Weis M, Heeschen C, Glassford AJ, Statins have biphasic effects on angiogenesis. Circulation 2002;105:739-45
   PubMed Web of Science ®Google Scholar
• Alonso DF, Farina HG, Skilton G, Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998;50:83-93
   PubMed Web of Science ®Google Scholar
• Kusama T, Mukai M, Iwasaki T, 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002;122:308-17
   PubMed Web of Science ®Google Scholar
• Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004;90:635-7
   PubMed Web of Science ®Google Scholar
• Dale KM, Coleman CI, Henyan NN, Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80
   PubMed Web of Science ®Google Scholar
• Bonovas S, Filioussi K, Tsavaris N, Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006;24:4808-17
   PubMed Web of Science ®Google Scholar
• Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J cancer 2006;120:833-43
   Web of Science ®Google Scholar
• Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-19
   PubMed Web of Science ®Google Scholar
• Haukka J, Sankila R, Klaukka T, Incidence of cancer and statin usage-record linkage study. Int J Cancer 2010;126:279-84
   PubMed Web of Science ®Google Scholar
• Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008;44:2122-32
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Glynn RJ, Avorn J, Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27-33
   PubMed Web of Science ®Google Scholar
• Blais L, Desgagne A, LeLorier J. 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000;160:2363-8
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Gardner JS, Malone KE, The association between 3-hydroxy-3-methylglutaryl-coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women. Cancer 2004;100:2308-16
   PubMed Web of Science ®Google Scholar
• Cauley JA, Zmuda JM, Lui LY, Lipid-lowering drug use and breast cancer in older women: a prospective study. J Women's Health 2003;12:749-56
   PubMed Web of Science ®Google Scholar
• Graaf MR, Beiderbeck AB, Egberts AC, The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-94
   PubMed Web of Science ®Google Scholar
• Poynter JN, Gruber SB, Higgins PD, Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92
   PubMed Web of Science ®Google Scholar
• Shannon J, Tewoderos S, Garzotto M, Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-25
   PubMed Web of Science ®Google Scholar
• Khurana V, Bejjanki HR, Caldito G, Statins reduce the risk of lung cancer: a large case-control study of US veterans. Chest 2007;131:1282-8
   PubMed Web of Science ®Google Scholar
• Khurana V, Sheth A, Caldito G, Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 2007;34:260-5
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Johnson ML, Hachem C, Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009;136:1601-8
   PubMed Web of Science ®Google Scholar
• Goldstein MR, Mascitelli L, Pezzetta F. Do statin prevent or promote cancer? Curr Oncol 2008;15:76-7
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30
   PubMed Web of Science ®Google Scholar
• Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 2011;71:1763-71
   PubMed Web of Science ®Google Scholar
• Farwell WR, Scranton RE, Lawler EV, The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008;100:134-9
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case- control studies. BMC Cancer 2011;11:409
   PubMed Web of Science ®Google Scholar
• Friedman GD, Flick D, Udaltsova N, Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36
   PubMed Web of Science ®Google Scholar
• Chiang CW, Chen CY, Chiu HF, Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol drug Saf 2007;16:412-21
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tsai SS, Tiao MM, Epidemiologic features of CKD in Taiwan. Am J Kidney Dis 2007;49:46-55
   PubMed Web of Science ®Google Scholar
• Coogan PF, Rosenberg L, Palmer JR, Statin use and the risk of breast and prostate cancer. Epidemiology 2002;13:262-7
   PubMed Web of Science ®Google Scholar
• Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006;58:3-18
   PubMed Web of Science ®Google Scholar
• Meier CR, Scheinger RG, Kraenzlin ME, HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10
   PubMed Web of Science ®Google Scholar
• Rejnmark L, Plsen ML, Johnsen SP, Hip fracture risk in statin users- a population-based Danish case-control study. Osteoporos Int 2004;15:452-8
   PubMed Web of Science ®Google Scholar
• Wang PS, Solomon DH, Mogun H, HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3211-16
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Center for Drugs Statistics Methodology. ATC Index with DDDs 2003. WHO: Oslo, 2003
   Google Scholar
• Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011;54:2009-15
   PubMed Web of Science ®Google Scholar
• Goldstein MR, Mascitelli L, Pezzetta F. The double-edged sword of statin immunomodulation. Int J Cardiol 2009;135:128-30
   PubMed Web of Science ®Google Scholar
• Mausner-Fainberg K, Luboshits G, Mor A, The effect of HMG-CoA reductase inhibitors on naturally occurring CD+4CD+25 T cells. Atherosclerosis 2008;197:829-39
   PubMed Web of Science ®Google Scholar
• Raemer PC, Kohl K, Watzl C. Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation. Eur J Immunol 2009;39:1456-65
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Katznelson S, Laks H, Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Villa A, Ortego M, 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002;161:17-26
   PubMed Web of Science ®Google Scholar
• Danesh FR, Sadeghi MM, Amro N, 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci 2002;99:8301-5
   PubMed Web of Science ®Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-19
   PubMed Web of Science ®Google Scholar
• Shibata MA, Avanaugh C, Shibata E, Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003;24:453-9
   PubMed Web of Science ®Google Scholar
• Rao S, Porter DC, Chen X, Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci 1999;96:7797-802
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tsai SS, Tiao MM, Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf 2010;19:745-51
   PubMed Web of Science ®Google Scholar